On October 7, the Washington Post reported that federal health officials are preparing a stopgap order that would let state-licensed compounding pharmacies temporarily dispense certain unapproved peptides — including names this blog’s readers know well: BPC-157, TB-500, KPV, and MOTS-c.
Here’s the honest breakdown: what we know, what we don’t, and why it matters.
What happened
- September 2023: the FDA moved 19 peptides into “Category 2” — substances compounding pharmacies should not touch, citing safety concerns.
- February 2026: HHS signaled a reversal, calling the restrictions a mistake.
- April 2026: the FDA removed 12 peptides from Category 2 after their nominations were withdrawn. Important nuance: removal from Category 2 is not approval to compound. The peptides landed in a regulatory gap — no longer flagged, but not cleared either.
- July 2026: the FDA’s Pharmacy Compounding Advisory Committee voted to recommend 6 of 7 evaluated peptides for the official 503A bulks list — BPC-157, TB-500, KPV, MOTS-c, epitalon, and semax — against the recommendation of the FDA’s own scientists, who said the safety data wasn’t there. The committee voted no on the seventh, emideltide.
- Now: the Post reports HHS is preparing an interim order allowing temporary dispensing while formal rulemaking is written. Timing unknown. Which peptides unknown. HHS declined to comment.
The pushback
The FDA’s own scientists aren’t on board. Per Citeline (October 8), drug-center staff said they will not recommend temporary compounding of unapproved peptides. Safety groups warned after the July vote that gaps in safety and efficacy data remain unresolved.
Honest read
This is a policy fight, not a scientific verdict. Nobody in this story is claiming new safety data appeared. The disagreement is about whether supervised pharmacy compounding — with guardrails like patient disclosures, adverse-event reporting, and use tracking, which the compounders’ alliance itself proposed — is better than the current reality, where demand flows to unregulated sellers with no oversight at all.
And the principle this blog runs on cuts both ways: regulatory status is not a verdict on whether a molecule works. It’s a statement about what data regulators have accepted, and through which process. Hype and dismissal both mislead.
What it would mean
If the stopgap happens, these peptides move from the gray market into licensed pharmacies — dispensed with a prescription, with at least some reporting attached. That’s a stricter channel than today’s free-for-all.
But the standard for buyers shouldn’t change either way: third-party testing, lot-matched certificates of analysis, no exceptions. A pharmacy label is not a COA. Read the trial before you buy the vial.
What we don’t know
Everything that matters for timing: which peptides, when it takes effect, and whether FDA leadership overrules its own scientists. We’ll update this post as the rulemaking develops.
Sources: Washington Post reporting (Oct 7, via Becker’s Hospital Review); Citeline (Oct 8) on FDA staff pushback; background on the July PCAC vote via Pharmacy Practice News and Drug Topics.